Bioequivalence and tolerability of two clopidogrel salt preparations, besylate and bisulfate: A randomized, open-label, crossover study in healthy Korean male subjects

Clinical Therapeutics

Volumn 31, Issue 4, 2009, Pages 793-803

  Kim, Sung Doo ^a,b   Kang, Wonku ^c   Lee, Hae Won ^a,b   Park, Dae Jin ^a,d   Ahn, Ju Hee ^a,b   Kim, Mi Jin ^a,b   Kim, Eun Young ^e   Kim, Sung Wuk ^f   Nam, Hee Sook ^f   Na, Hye Jung ^f   Yoon, Young Ran ^a,b  

^a Kyungpook National University Hospital   (South Korea)

^b Kyungpook National University School of Medicine   (South Korea)

^c Catholic University of Daegu   (South Korea)

^d Kosin University   (South Korea)

^e Samsung Medical Center   (South Korea)

^f HanAll Pharmaceutical Co Ltd   (South Korea)

Author keywords

bioequivalence; clopidogrel; clopidogrel besylate; pharmacodynamics; pharmacokinetics; platelet aggregation

Indexed keywords

2 (2 CHLOROPHENYL) 2 (4,5,6,7 TETRAHYDROTHIENO[3,2 C]PYRIDIN 5 YL)ACETIC ACID; ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; CLOPIDOGREL BESYLATE; PLAVID; UNCLASSIFIED DRUG;

ABDOMINAL DISCOMFORT; ADULT; ANTICOAGULATION; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; DRUG INHIBITION; DRUG TOLERABILITY; FATIGUE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; KOREA; LABORATORY TEST; LOADING DRUG DOSE; MAINTENANCE DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PHYSICAL EXAMINATION; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; THROMBOCYTE AGGREGATION; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; VITAL SIGN;

ADENOSINE DIPHOSPHATE; ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; HUMANS; KOREA; MALE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; SALTS; TANDEM MASS SPECTROMETRY; THERAPEUTIC EQUIVALENCY; TICLOPIDINE; YOUNG ADULT;

EID: 65549156497     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2009.04.017     Document Type: Article

References (37)

1. Yusuf S., Zhao F., Mehta S.R., et al., the Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation [published corrections appear in N Engl J Med. 2001;345:1506, 1716]. N Engl J Med. 345 (2001) 494-502
2. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 348 (1996) 1329-1339
3. Savi P., Labouret C., Delesque N., et al. P2y(12), a new platelet ADP receptor, target of clopidogrel. Biochem Biophys Res Commun. 283 (2001) 379-383
4. Creager M.A. Results of the CAPRIE trial: Efficacy and safety of clopidogrel. Clopidogrel versus aspirin in patients at risk of ischaemic events. Vasc Med. 3 (1998) 257-260
5. Clarke T.A., and Waskell L.A. The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab Dispos. 31 (2003) 53-59
6. Herbert J.M., Frehel E., Vallee G., et al. Clopidogrel, a novel antiplatelet and antithrombotic agent. Cardiovasc Drug Rev. 11 (1993) 180-198
7. Caplain H., Donat F., Gaud C., and Necciari J. Pharmacokinetics of clopidogrel. Semin Thromb Hemost. 25 Suppl 2 (1999) 25-28
8. Geiger J., Teichmann L., Grossmann R., et al. Monitoring of clopidogrel action: Comparison of methods. Clin Chem. 51 (2005) 957-965
9. Rand M.L., Leung R., and Packham M.A. Platelet function assays. Transfus Apher Sci. 28 (2003) 307-317
10. O'Donoghue M., and Wiviott S.D. Clopidogrel response variability and future therapies: Clopidogrel: Does one size fit all?. Circulation. 114 (2006) e600-e606
11. Agrawal H., Kaul N., Paradkar A., and Mahadik K.R. Stability indicating HPTLC determination of clopidogrel bisulphate as bulk drug and in pharmaceutical dosage form. Talanta. 61 (2003) 581-589
12. Gomez Y., Adams E., and Hoogmartens J. Analysis of purity in 19 drug product tablets containing clopidogrel: 18 Copies versus the original brand. J Pharm Biom Anal. 34 (2004) 341-348
13. inventors; assignee. Doser S., Glanzer K., and Helm A.G. Benzene sulfonic acid salts of clopidogrel, methods for preparing same, and pharmaceutical formulations thereof. United States patent application US 2005/0203122A1 (September 15, 2005). http://www.patentlens.net/patentlens/structured.cgi?patnum=US_2005/0203122_A1#show Accessed February 6, 2009
14. Byrn S., Pfeiffer R., Ganey M., et al. Pharmaceutical solids: A strategic approach to regulatory considerations. Pharm Res. 12 (1995) 945-954
15. Borges N.C., Mendes G.D., Borges A., et al. Ticlopidine quantification in human plasma by high-performance liquid chromatography coupled to electrospray tandem mass spectrometry. Application to bioequiva-lence study. J Mass Spectrom. 39 (2004) 1562-1569
16. Lainesse A., Ozalp Y., Wong H., and Alpan R.S. Bioequivalence study of clopidogrel bisulfate film-coated tablets. Arzneimittelforschung. 54 (2004) 600-604
17. Caplain H. Enhanced antiplatelet effects of clopidogrel plus acetylsalicylic acid compared with acetylsalicylic acid alone or combined with extended-release dipyridamole in healthy volunteers. Cerebrovasc Dis. 19 (2005) 214-219
18. Müller I., Besta F., Schulz C., et al. Prevalence of clopidogrel nonresponders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost. 89 (2003) 783-787
19. Weerakkody G.J., Brandt J.T., Payne C.D., et al. Clopidogrel poor responders: An objective definition based on Bayesian classification. Platelets. 18 (2007) 428-435
20. Ritschel W.A. Handbook of Basic Pharmacokinetics-Including Clinical Applications. 4th ed (1992), Drug Intelligence Publications, Hamilton, Ill
21. Intravenous dose. In: Rowland M., and Tozer T.N. (Eds). Clinical Pharmacokinetics, Concepts and Applications. 3rd ed (1995), Williams & Wilkins, Media, Pa 18-33
22. Farid N.A., Payne C.D., Small D.S., et al. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther. 81 (2007) 735-741
23. Duke W.W. The relation of blood platelets to hemorrhagic disease. JAMA 250 (1983) 1201-1209
24. Chow S.-C., and Liu J.-P. Design and Analysis of Bioavailability and Bioequivalence Studies (1992), Marcel Dekker, New York, NY
25. Schuirmann D.J. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm. 15 (1987) 657-680
26. US Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry. Statistical approaches to establishing bioequivalence. Accessed July 1. 2008. http://www.fda.gov/Cder/guidance/3616fnl.htm
27. Bahrami G., Mohammadi B., and Si-sakhtnezhad S. High-performance liquid chromatographic determination of inactive carboxylic acid metabolite of clopidogrel in human serum: Application to a bioequiva-lence study. J Chromatogr B Analyt Technol Biomed Life Sci. 864 (2008) 168-172
28. Robinson A., Hillis J., Neal C., and Leary A.C. The validation of a bioanalytical method for the determination of clopidogrel in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 848 (2007) 344-354
29. Thebault J.J., Kieffer G., and Cariou R. Single-dose pharmacodynamics of clopidogrel. Semin Thromb Haemost. 25 Suppl 2 (1999) 3-8
30. Rao T.R., Usha P.R., Naidu M.U., et al. Bioequivalence and tolerability study of two brands of clopidogrel tablets, using inhibition of platelet aggregation and pharmacodynamic measures. Curr Ther Res Clin Exp. 64 (2003) 685-696
31. Nirogi R.V., Kandikere V.N., Shukla M., et al. Quantification of clopidogrel in human plasma by sensitive liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom. 20 (2006) 1695-1700
32. Taubert D., Kastrati A., Harlfinger S., et al. Pharmacokinetics of clopidogrel after administration of a high loading dose. Thromb Haemost. 92 (2004) 311-316
33. Schroeder W.S., Ghobrial L., and Gandhi P.J. Possible mechanisms of druginduced aspirin and clopidogrel resistance. J Thromb Thrombolysis. 22 (2006) 139-150
34. Kim K.A., Park P.W., Hong S.J., and Park J.Y. The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: A possible mechanism for clopidogrel resistance. Clin Pharmacol Ther. 84 (2008) 236-242
35. *3 genotype on the pharmacokinetics and antiplatelet effect of clopidogrel in healthy subjects. Eur J Clin Pharmacol. 64 (2008) 589-597
36. Small D.S., Farid N.A., Payne C.D., et al. Effects of the proton pump inhibitor lansoprazole on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogrel. J Clin Pharmacol. 48 (2008) 475-484
37. Angiolillo D.J., Fernandez-Ortiz A., Bernardo E., et al. Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting. Thromb Res. 115 (2005) 101-108